EYPT · Eyepoint Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M | $34.44M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $221.04M | $132.93M | $64.66M | $49.64M | $28.50M | $17.42M |
| SG&A | $51.61M | $52.36M | $40.10M | $34.82M | $25.57M | $20.73M |
| Total Operating Expenses | $274.81M | $189.13M | $121.08M | $141.04M | $92.22M | $71.73M |
| D&A | $1.54M | $1.54M | $464.0K | $396.0K | $311.0K | $189.0K |
| Operating Income | ($243.43M) | ($145.85M) | ($75.07M) | ($99.64M) | ($55.28M) | ($37.29M) |
| Interest Expense | $33.0K | $14.0K | $1.25M | $3.19M | $5.50M | $7.26M |
| Income Tax | $279.0K | $90.0K | $83.0K | $0 | $0 | $0 |
| Net Income | ($231.96M) | ($130.87M) | ($70.80M) | ($102.25M) | ($58.42M) | ($45.39M) |
| EPS - Basic | ($3.17) | ($2.32) | ($1.82) | ($2.03) | - | - |
| EPS - Diluted | ($3.17) | ($2.32) | ($1.82) | ($2.03) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $101.82M | $99.70M | $281.26M | $95.63M | $178.59M | $44.91M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $1.81M | $2.31M | $3.91M | $2.89M | $3.62M | $5.34M |
| Accounts Payable | $10.49M | $11.72M | $6.50M | $5.92M | $7.38M | $4.81M |
| Current Assets | $328.65M | $383.31M | $344.80M | $172.81M | $237.75M | $63.12M |
| Total Assets | $364.00M | $418.46M | $355.18M | $180.36M | $263.37M | $91.72M |
| Current Liabilities | $37.02M | $49.05M | $63.26M | $34.54M | $23.66M | $14.89M |
| Long-term Debt | - | - | - | $29.31M | $36.56M | $37.98M |
| Total Liabilities | $57.88M | $81.96M | $88.86M | $83.99M | $78.99M | $73.18M |
| Stockholders' Equity | $306.11M | $336.50M | $266.32M | $96.37M | $184.38M | $18.54M |
| Retained Earnings | ($1.10B) | ($873.02M) | ($742.15M) | ($671.35M) | ($569.10M) | ($510.68M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($240.11M) | ($126.23M) | $1.88M | ($65.00M) | ($50.10M) | ($14.44M) |
| Investing Cash Flow | $68.58M | ($219.35M) | ($3.31M) | ($17.27M) | ($33.12M) | ($362.0K) |
| Financing Cash Flow | $173.65M | $164.02M | $187.07M | ($690.0K) | $216.90M | $37.49M |
| CapEx | $3.28M | $4.05M | $3.48M | $2.15M | $156.0K | $362.0K |
| Free Cash Flow | ($243.39M) | ($130.28M) | ($1.61M) | ($67.16M) | ($50.25M) | ($14.80M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | -108.3% |
| EBITDA margin | -771.1% | -333.5% | -162.1% | -239.7% | -148.8% | -107.7% |
| Net margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | -131.8% |
| Free cash flow margin | -775.8% | -301.1% | -3.5% | -162.2% | -136.0% | -43.0% |
| FCF / Net income | 1.05 | 1.00 | 0.02 | 0.66 | 0.86 | 0.33 |
| R&D / Revenue | 704.6% | 307.2% | 140.5% | 119.9% | 77.2% | 50.6% |
| SG&A / Revenue | 164.5% | 121.0% | 87.1% | 84.1% | 69.2% | 60.2% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -63.7% | -31.3% | -19.9% | -56.7% | -22.2% | -49.5% |
| Return on equity | -75.8% | -38.9% | -26.6% | -106.1% | -31.7% | -244.8% |
| Return on invested capital | - | - | - | -62.6% | -19.8% | -52.1% |
| Liquidity | ||||||
| Current ratio | 8.88 | 7.81 | 5.45 | 5.00 | 10.05 | 4.24 |
| Quick ratio | 8.83 | 7.77 | 5.39 | 4.92 | 9.90 | 3.88 |
| Cash ratio | 2.75 | 2.03 | 4.45 | 2.77 | 7.55 | 3.02 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.30 | 0.20 | 2.05 |
| Debt / Assets | - | - | - | 0.16 | 0.14 | 0.41 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -7376.8x | -10418.1x | -60.2x | -31.2x | -10.1x | -5.1x |
| Equity multiplier | 1.19 | 1.24 | 1.33 | 1.87 | 1.43 | 4.95 |
| Liabilities / Assets | 0.16 | 0.20 | 0.25 | 0.47 | 0.30 | 0.80 |
| Efficiency | ||||||
| Asset turnover | 0.09 | 0.10 | 0.13 | 0.23 | 0.14 | 0.38 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.0x | 0.0x | 3.4x | 1.0x | - | - |
| P / S | 0.0x | 0.0x | 19.5x | 2.4x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -27.5% | -6.0% | 11.1% | 12.1% | 7.3% | 653.4% |
| Revenue CAGR (3y) | -8.8% | 5.4% | 10.1% | 108.5% | 183.6% | 65.9% |
| Revenue CAGR (5y) | -1.8% | 56.8% | 95.3% | 40.6% | 86.9% | 5.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -66.9% | -94.3% | 24.7% | -80.3% | -48.2% | 4.4% |
| Net income growth (YoY) | -77.2% | -84.9% | 30.8% | -75.0% | -28.7% | 47.3% |
| EPS growth (YoY) | -36.6% | -27.5% | 10.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -86.8% | -8001.9% | 97.6% | -33.6% | -239.6% | 74.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -9.0% | 26.4% | 176.4% | -47.7% | 894.4% | 122.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$61.57M totalLicense And Collaboration Agreement$16.73M · 27.2%
Product Rights Agreement$15.90M · 25.8%
Royalty$13.04M · 21.2%
Royalty Purchase Agreement$12.70M · 20.6%
YUTIQProduct$1.60M · 2.6%
Product$1.60M · 2.6%
Geographic
$31.37M totalUS$29.98M · 95.6%
CN$1.29M · 4.1%
GB$100.0K · 0.3%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.77
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing EyePoint Pharmaceuticals against the 5 most active filers in the same SIC group.